- About Us
- Advertise
- Contact Us
- Editorial Info
- Editorial Contacts
- Editorial Advisory Board
- Do Not Sell My Personal Information
- Privacy Policy
- Terms and Conditions
© 2024 MJH Life Sciences™ and Pharmaceutical Technology. All rights reserved.
Featured Content
Why Are Pharmaceutical Companies Reluctant to Adopt Cloud Technologies?
Mar 4th 2024
Despite its understandable hesitancy, the pharma industry is facing a need for more widespread adoption of cloud-based solutions.
Training for Operational Excellence
Dec 3rd 2023
The bio/pharmaceutical industry is struggling with the challenge of staffing and training.
Billions of Reasons to be Buoyant
Sep 2nd 2023
Pharma's ability to continually reinvent itself will be critical in growing future business operations.
Unpacking Amgen v. Sanofi
Aug 31st 2023
Exploring the state of pharma patents following the Supreme Court’s Amgen v. Sanofi decision.
Latest Videos
Latest News
NightHawk Biosciences Shifts into a Pure-Play Large-Molecule CDMO
December 20th 2023
Following the divestiture of its Elusys subsidiary and other non-core assets, NightHawk Biosciences will transform into a pure-play large-molecule CDMO.
Bristol Myers Squibb and SystImmune Enter Global ADC Collaboration Worth Potentially up to $8.4 Billion
December 19th 2023
Bristol Myers Squibb and SystImmune plan to co-develop and co-commercialize lead ADC candidate for cancer treatment in US.
RoslinCT to Manufacture CRISPR-Based Gene Therapy Casgevy
December 14th 2023
RoslinCT will manufacture Vertex Pharmaceuticals’ CRISPR-based gene therapy, Casgevy, recently approved for treating sickle cell disease and β thalassemia.
Sanofi to Terminate Rare Disease Drug Licensing Agreement with Maze Therapeutics in Wake of FTC’s Challenge
December 13th 2023
Sanofi has issued a statement expressing its disappointment with FTC’s decision to block an exclusive licensing agreement with Maze Therapeutics for a rare disease drug candidate.
AbbVie to Acquire ImmunoGen in Deal Valued at $10.1 Billion
December 8th 2023
AbbVie’s proposed acquisition of ImmunoGen is expected to accelerate AbbVie's entry into the commercial market for ovarian cancer and includes ImmunoGen’s flagship cancer therapy, ELAHERE (mirvetuximab soravtansine-gynx).
Genentech and NVIDIA Form AI Research Collaboration for Drug Discovery and Development
November 29th 2023
Under this multi-year collaboration, Genentech and NVIDIA will use AI to optimize and accelerate each company’s platforms to discover and develop innovative therapeutics.
Lithuania Set to Become Home to Largest Biotech City
November 24th 2023
The largest biotech hub is set to be built in Lithuania by Northway Group.
Industry Responds to the UK’s Autumn Statement
November 23rd 2023
UK industry body, ABPI, has responded positively to the recent Autumn Statement.
Novartis and Legend Biotech Sign Exclusive License Agreement for CAR-T Therapies
November 15th 2023
Novartis and Legend Biotech seek to advance certain CAR-T cell therapy candidates targeting Delta-like ligand protein 3.
Salary Survey for Pharma Scientists Shows Increase of 6.7% Since 2022
October 31st 2023
A recent AAPS Salary Survey shows a rising trend in compensation for pharmaceutical scientists since 2022.